Oesophagus / Esofago (C15.9) - Prognostic significance of preoperative serum CA 72-4 and CA 242 in patients with esophageal squamous cell carcinoma
Keywords:
esophageal squamous cell carcinoma, CA 72-4, CA 242, prognostic factor, survivalAbstract
Aims: The aim of this study was to determine the prognostic value of CA 72-4 and CA 242 in esophageal squamous cell carcinoma (ESCC). Materials and Methods: From January 2006 to December 2007, a retrospective analysis of 192 consecutive patients with ESCC was carried out. Univariate and multivariate analyses were performed to evaluate the prognostic parameters. Results: The positive rates for CA 72-4 and CA 242 were 18.8% (36/192) and 7.3% (14/192), respectively. Patients with CA 72-4 ≤6 U/ml showed a significantly better 5-year overall survival than patients with CA 72-4 >6 U/ml (42.3% vs. 5.6%; p<0.001). Patients with CA 242 ≤10 U/ml also showed a significantly better 5-year overall survival than patients with CA 242 >10 U/ml (37.6% vs. 7.1%; p=0.011). Multivariate analyses demonstrated that differantiation (p=0.021), CA 72-4 (p=0.037), T grade (p=0.012) and N staging (p<0.001) were independent prognostic factors. Conclusion: CA 72-4 is an independent predictive factor for long-term survival in ESCC. CA 72-4 shows a higher accuracy in predicting T grades, N stagings and overall survival than CA 242. Although CA 72-4 and CA 242 show significant association with poorer prognosis, its low sensitivity limits the clinical application.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.